^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    RP3

    i
    Other names: RP3, genetically modified HSV-1, genetically modified herpes simplex type 1 virus
    Associations

    News

    Trials
    Company:
    Replimune
    Drug class:
    CTLA4 inhibitor, CD137 modulator, CD40 stimulant
    Related drugs:
    Associations

    News

    Trials
    4d
    RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC (clinicaltrials.gov)
    P2, N=5, Terminated, Replimune Inc. | Trial completion date: Mar 2027 --> Aug 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2027 --> Aug 2025; Business reasons.
    Trial completion date • Trial termination • Trial primary completion date • Mismatch repair • pMMR
    |
    EGFR (Epidermal growth factor receptor)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • RP3 • sturlimogene erparepvec (RP2)
    24d
    RPx: A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, Replimune Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    RP3 • Tudriqev (vusolimogene oderparepvec-wtpg) • sturlimogene erparepvec (RP2)
    6ms
    RPx: A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 (clinicaltrials.gov)
    P=N/A, N=50, Not yet recruiting, Replimune Inc. | Initiation date: Jun 2025 --> Nov 2025
    Trial initiation date
    |
    RP3 • Tudriqev (vusolimogene oderparepvec-wtpg) • sturlimogene erparepvec (RP2)
    11ms
    RPx: A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 (clinicaltrials.gov)
    P=N/A, N=50, Not yet recruiting, Replimune Inc.
    New trial
    |
    RP3 • Tudriqev (vusolimogene oderparepvec-wtpg) • sturlimogene erparepvec (RP2)
    over1year
    Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours (clinicaltrials.gov)
    P1, N=123, Active, not recruiting, Replimune Inc. | Trial completion date: Apr 2024 --> Nov 2026 | Trial primary completion date: Apr 2024 --> Nov 2026
    Trial completion date • Trial primary completion date • Combination therapy
    |
    Opdivo (nivolumab) • RP3
    almost2years
    RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC (clinicaltrials.gov)
    P2, N=4, Active, not recruiting, Replimune Inc. | N=60 --> 4
    Enrollment change • Combination therapy • Oncolytic virus • Mismatch repair • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • RP3 • sturlimogene erparepvec (RP2)
    2years
    Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN (clinicaltrials.gov)
    P2, N=0, Withdrawn, Replimune Inc. | N=130 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • Combination therapy • Oncolytic virus • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    CDKN2A negative
    |
    Opdivo (nivolumab) • carboplatin • paclitaxel • RP3
    2years
    RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, Replimune Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Oncolytic virus • Mismatch repair • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • RP3 • sturlimogene erparepvec (RP2)
    2years
    RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC (clinicaltrials.gov)
    P2 | N=60 | Not yet recruiting | Sponsor: Replimune Inc. | Trial primary completion date: Jan 2027 ➔ Apr 2027
    Trial primary completion date • Combination therapy • Oncolytic virus
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • RP3
    2years
    Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours (clinicaltrials.gov)
    P1, N=123, Active, not recruiting, Replimune Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy
    |
    Opdivo (nivolumab) • RP3
    2years
    An open-label clinical trial of RP2 and RP3 oncolytic immunotherapy in combination with atezolizumab plus bevacizumab for the treatment of patients with advanced colorectal carcinoma. (ASCO-GI 2024)
    Safety will be assessed by physical examination, clinical laboratory evaluations, vital signs, and monitoring for adverse events (AEs; including serious AEs). Clinical trial information: NCT05733611.
    Clinical • Combination therapy • Oncolytic virus • Metastases
    |
    MSI (Microsatellite instability) • CD40 (CD40 Molecule)
    |
    MSI-H/dMMR • CSF2 expression
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • RP3 • sturlimogene erparepvec (RP2)
    2years
    RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Replimune Inc. | Initiation date: Oct 2023 --> Feb 2024
    Trial initiation date • Combination therapy • Oncolytic virus • Metastases
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • RP3